Questo è quello che abbiamo trovato per te
La nuova semplificazione sta cominciando ad avere effetti su milioni di pazienti cronici che ora hanno la possibilità di avere accesso subito a un farmaco salva vita nella farmacia sotto casa
Con una singola iniezione e dopo un mese i primi risultati
This diagnostic study assesses the accuracy of an investigational blood-based circulating tumor DNA test for detection of colorectal cancer in an asymptomatic average-risk population.
“Ritardi preparazione delle terapie della farmacia ospedaliera”
“Ritardi preparazione delle terapie della farmacia ospedaliera”
A base di cellule pancreatiche derivate da staminali, studio 1/2
Studio firmato da due docenti di Unibz con un collega di Colonia
Via alla seconda edizione del Barometro del patient engament
Studio, obiettivo sarà indirizzare da subito questi pazienti verso altre cure
Consentirà di personalizzare cure sin dal momento della diagnosi
Studio su Nature Genetics, possibile scegliere subito altre cure
Elacestrant, appena approvato da AIFA. Studio IEO di Milano
In campo squadre dei Centri oncoematologia pediatrica d’Italia
39 quelle firmate dagli oncologi Aiom. Il caso delle terapie neoadiuvanti
Introduction
The cuff leak test (CLT) is hypothesised to help optimise extubation by assessing for laryngeal oedema which, if unrecognised and untreated, could lead to post-extubation stridor, post-extubation airway obstruction, and reintubation. However, the diagnostic accuracy of the CLT to detect post-extubation stridor (and hence potentially airway obstruction) remains uncertain. Given the equipoise that exists surrounding the CLT, we are conducting a pilot randomised clinical trial (RCT) examining the CLT as part of the pathway to extubation. Herein, we report the protocol for the Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients (COSMIC): a Pilot Feasibility Randomized Clinical trial (RCT).
Methods and analysis
This is a multicentre, international, parallel-group, pragmatic, pilot RCT. We will enrol 100 mechanically ventilated patients in the intensive care unit (ICU) who are deemed ready for extubation and have at least one risk factor for laryngeal oedema. In the intervention arm, respiratory therapists will perform a qualitative CLT before extubation. If a patient passes the CLT (suggesting no laryngeal oedema), extubation will be performed in keeping with standard care. If the patient fails the CLT (suggesting laryngeal oedema), extubation will be delayed allowing for administration of dexamethasone, consideration of diuresis, and the CLT will be repeated in 12–24 hours. In the control arm, patients will be extubated without completing a CLT, without steroid administration, and without delay. Randomization will be by a 1:1 allocation, stratified by centre. The primary feasibility outcomes will include recruitment and protocol adherence. Secondary outcomes will include post-extubation stridor, reintubation within 72 hours, emergency surgical airway within 72 hours, and ICU and hospital mortality within 30 days.
Ethics and dissemination
This trial has been approved by Clinical Trials Ontario, Hamilton Integrated Research Ethics Board, State of Kuwait Ministry of Health, University of Texas Health Committee for the Protection of Human Subjects and Brant Community Health Systems Research Ethics Committee. The trial has received a No Objection Letter from Health Canada. Trial results will be disseminated via publication in peer-reviewed journals.
Trial registration number
NCT05456542.
Boom di studi scientifici sul tema, + 5.000% in 10 anni
